Renal ablation for treatment of hypertension without Symplicity catheter: The first human experience

被引:0
|
作者
Honarvar, Mehrdad [1 ]
Amirpour, Afshin [2 ]
Pourmoghaddas, Masoud [3 ]
机构
[1] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Cardiac Rehabil Res Ctr, Esfahan, Iran
[2] Isfahan Univ Med Sci, Sch Med, Dept Cardiol, Esfahan, Iran
[3] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Isfahan Cardiovasc Res Ctr, Esfahan, Iran
关键词
Denervation; Resistant Hypertension; Catheter;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Hypertension (HTN) treatment has remained insufficient. New modalities such as "Symplicity method" for the treatment of HTN are a priority, especially in patients with resistant hypertension. In this study, we describe our first experience with a novel percutaneous treatment modality, without using Symplicity catheter. METHODS: 30 Patients who were resistant to at least three types of antihypertensive medical therapy were selected. Patients received percutaneous renal artery denervation, without Symplicity catheter method, and were followed up for 1 week, 1, 3, and 6 months later after treatment. Ambulatory 24-hour blood pressure (BP) Holter was performed 1 week before intervention and after 1 month. The primary outcome was change in 24-hour ambulatory BP and change in office and home-based BP measurements. RESULTS: The mean age of the studied patients was 52 +/- 15.4 years and 43.3% (n = 13) were female. Systolic and diastolic BP at baseline was 163 +/- 17.2 and 95 +/- 8.2 mmHg, respectively. Patients took 3.6 +/- 1.3 hypertensive medications. Systolic and diastolic BP at 1-week, 1-month, 3-month and 6-month after renal denervation significantly decreased compared to the baseline (P < 0.0001). Average BP derived from 24-hour ambulatory BP monitoring changed in parallel with office-based BP measurements. Most of patients (50%) who underwent renal denervation had reductions of 10 mmHg or greater in systolic BP and 56.7% of them had reductions of 5 mmHg or greater in diastolic BP. 33.3% of patients also achieved the target of systolic BP less than 140 mmHg and 60% achieved the target of diastolic BP less than 90 mmHg. No patients showed vascular damage at final angiography. CONCLUSION: Catheter based renal ablation was associated with a significant reduction in both systolic and diastolic BP, on top of maximal medical therapy, which persisted throughout 6 months follow-up in the first-in-man study without the Symplicity catheter.
引用
收藏
页码:82 / 88
页数:7
相关论文
共 50 条
  • [31] Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial
    Esler, Murray D.
    Boehm, Michael
    Sievert, Horst
    Rump, Christian L.
    Schmieder, Roland E.
    Krum, Henry
    Mahfoud, Felix
    Schlaich, Markus P.
    EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1752 - 1759
  • [32] Long-Term Follow-up of Catheter-Based Renal Denervation in Patients with Treatment Resistant Hypertension: The Symplicity HTN-2 Trial
    Murray, Esler
    Henry, Krum
    Marcus, Schlaich
    Roland, Schmieder
    Michael, Boehm
    JOURNAL OF CLINICAL HYPERTENSION, 2013, 15
  • [33] Renal sympathetic denervation for the treatment of resistant hypertension with chronic renal failure: first-in-man experience
    Luo Di
    Zhang Xin
    Lu Cheng-zhi
    CHINESE MEDICAL JOURNAL, 2013, 126 (07) : 1392 - 1393
  • [34] SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients -
    Kario, Kazuomi
    Ogawa, Hisao
    Okumura, Ken
    Okura, Takafumi
    Saito, Shigeru
    Ueno, Takafumi
    Haskin, Russel
    Negoita, Manuela
    Shimada, Kazuyuki
    CIRCULATION JOURNAL, 2015, 79 (06) : 1222 - 1229
  • [35] Should catheter ablation be the first line of treatment for atrial fibrillation?
    Lindsay, Bruce D.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2009, 76 (09) : 503 - +
  • [36] Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
    Saraiva, Ana Filipa
    CURRENT HYPERTENSION REVIEWS, 2016, 12 (01) : 68 - 86
  • [37] The Pathophysiological Basis of Renal Nerve Ablation for the Treatment of Hypertension
    Ziakas, A.
    Gossios, T.
    Doumas, M.
    Karali, K.
    Megarisiotou, A.
    Stiliadis, I
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (01) : 23 - 29
  • [38] FIRST-IN-HUMAN CLINICAL EXPERIENCE WITH A NOVEL 4D ICE CATHETER DURING CATHETER ABLATION AND LAA CLOSURE PROCEDURES
    Reddy, Vivek Y.
    Doshi, Shephal K.
    Gidney, Brett A.
    Al-Ahmad, Amin
    Valderrabano, Miguel
    Neuzil, Petr
    Rackauskas, Gediminas
    Aidietis, Audrius
    Natale, Andrea
    HEART RHYTHM, 2021, 18 (09) : 1632 - 1633
  • [39] The First Human Experience With An Irrigated-tip Magnetic Catheter In Patients Undergoing Remote Ablation Of Atrial Fibrillation
    Santinelli, Vincenzo
    Radinovic, Andrea
    Vicedomini, Gabriele
    Paglino, Gabriele
    Augello, Giuseppe
    Gulletta, Simone
    Mazzone, Patrizio
    Ciconte, Giuseppe
    Sacchi, Stefania
    Pappone, Carlo
    CIRCULATION, 2008, 118 (18) : S984 - S984
  • [40] Catheter-based renal denervation for treatment of resistant hypertension
    Hatipoglu, Emine
    Ferro, Albert
    JRSM CARDIOVASCULAR DISEASE, 2013, 2